373226
Hdm2 E3 Ligase Inhibitor II, HLI373
The Hdm2 E3 Ligase Inhibitor II, HLI373, also referenced under CAS 502137-98-6, controls the biological activity of Hdm2 E3 Ligase. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
别名:
Hdm2 E3 Ligase Inhibitor II, HLI373, 5-(3-Dimethylaminopropylamino)-3,10-dimethyl-10H-pyrimido[4,5-b]quinoline-2,4-dione, 2HCl, MDM2 Inhibitor VI, MDM2 E3 Ligase Inhibitor II
InChI
1S/C18H23N5O2.2ClH/c1-21(2)11-7-10-19-15-12-8-5-6-9-13(12)22(3)16-14(15)17(24)23(4)18(25)20-16;;/h5-6,8-9,19H,7,10-11H2,1-4H3;2*1H
InChI key
WUEMKAQTAIRDOA-UHFFFAOYSA-N
SMILES string
O=C1C2=C(NCCCN(C)C)C3=C(C=CC=C3)N(C)C2=NC(N1C)=O.[2HCl]
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
cream
solubility
water: 50 mg/mL
shipped in
ambient
Quality Level
General description
A cell-permeable pyrimidoquinoline-dione compound that promotes cellular p53 and E3 ubiquitin ligase HDM2/MDM2 built-ups (optimal conc. = 5 µM in human retinal pigment epithelial RPE cells) via direct inhibition of MDM2-mediated p53 ubiquitination and MDM2 autoubiquitination, resulting in an upregulation of p53-dependent transcription activity (2.5-fold of basal in U2OS-based reporter assays; 5 µM 20 h treatment). Shown to induce apoptotic cell death in E1A-transformed, but not non-transformed, RPE cells (72% death; 10 µM 26 h treatment) and be more active toward wild-type p53-expressing than mutant p53-expressing cancer cells (≥67% vs. ≤37% death induction, respectively; 25 µM 30 h treatment).
Packaging
Packaged under inert gas
Other Notes
Kitagaki, J., et al. 2008. Mol. Cancer Ther.7, 2445.
Yang, Y., et al. 2005. Cancer Cell7, 547.
Yang, Y., et al. 2005. Cancer Cell7, 547.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Regulatory Review (Z)
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Viktoria K Ilic et al.
Biomolecules, 12(5) (2022-05-29)
The proto-oncogene MDM2 is frequently amplified in many human cancers and its overexpression is clinically associated with a poor prognosis. The oncogenic activity of MDM2 is demonstrated by its negative regulation of tumor suppressor p53 and the substrate proteins involved
相关内容
New Products: Antibodies, Assays, Small Molecules, Inhibitors, and Proteins
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持